Lantheus to Acquire Progenics

Lantheus to Acquire Progenics

  

Fried Frank acted as counsel to SVB Leerink as financial advisor to Lantheus Holdings, Inc. (Lantheus) in its definitive agreement to acquire Progenics Pharmaceuticals, Inc. (Progenics). Lantheus develops, manufactures, and commercializes innovative diagnostic imaging agents and products. Progenics is an oncology company developing innovative medicines and artificial intelligence. Under the terms of the agreement, Lantheus will acquire all of the issued and outstanding common shares of Progenics stock at a fixed exchange ratio. The transaction is expected to close in the first quarter of 2020.
 
The Fried Frank team was led by corporate partner Warren S. de Wied.

majormatters-detail.inc